REGENXBIO Presents RGX-202 Gene Therapy Updates at MDA Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy RGNX?
Source: PRnewswire
- Clinical Data Presentation: REGENXBIO will showcase clinical data on RGX-202 at the 2026 Muscular Dystrophy Association Conference, including preclinical and Phase I/II safety, biomarker, and functional data, which is expected to bolster investor confidence in the company's R&D capabilities.
- Key Presentation Schedule: Clinical Professor Carolina Tesi Rocha will present oral data on RGX-202 on March 11, 2026, at 11:45 AM, highlighting its potential in treating Duchenne muscular dystrophy, which may attract more attention and collaboration opportunities.
- Poster Presentation Insights: Dr. Steven Foltz from REGENXBIO will present research on microdystrophin's protective effects against pharmacologically induced cardiac damage in mice, further validating RGX-202's therapeutic mechanism and potentially advancing subsequent clinical studies.
- Symposium Details: The company will host a symposium titled “Advancing Duchenne Gene Therapy Trials in a New Era” on March 9, 2026, featuring industry experts discussing optimized trial design and interpretation, aimed at enhancing the understanding and application of gene therapies in the field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.080
Low
19.00
Averages
29.71
High
45.00
Current: 9.080
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO Announces Positive Interim Data for RGX-202 in Duchenne Muscular Dystrophy Trial
- Clinical Trial Progress: REGENXBIO has announced positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, indicating significant improvements in functionality, safety, and biomarkers, positioning it as a potential best-in-class gene therapy for Duchenne muscular dystrophy.
- Expert Data Presentation: The trial's principal investigator, Dr. Carolina Tesi-Rocha, Clinical Professor of Neurology at Stanford University School of Medicine, presented these findings at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, enhancing the therapy's academic recognition and industry visibility.
- Cardiac MRI Assessments: The new data includes cardiac MRI evaluations, suggesting RGX-202's potential in improving cardiac function, which is crucial for the overall health of Duchenne muscular dystrophy patients and may influence future treatment protocols.
- Optimistic Market Outlook: With positive clinical feedback, REGENXBIO is poised to carve out a niche in the competitive gene therapy market, attracting investor interest and potentially driving up the company's stock price.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and potentially receive compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting the critical importance of transparency in corporate communications.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, which underscores the importance of selecting qualified legal counsel.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that REGENXBIO made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating material misleading throughout the class period.
- Market Reaction: Following the revelation of REGENXBIO's true situation, investors experienced substantial losses, suggesting that the company's failure in information disclosure could have long-term negative impacts on its stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, highlighting the legal avenue available for investors to seek compensation for their losses.
See More
Regenxbio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regenxbio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by April 14, 2026, indicating significant legal risks that could impact the company's reputation and stock price.
- FDA Clinical Hold: On January 28, 2026, Regenxbio announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case found in trials, leading to a 17.9% drop in stock price on the same day, reflecting the direct impact of regulatory risks on the company's operations.
- Significant Stock Decline: Following the FDA announcement, Regenxbio's stock price fell from $13.41 to $11.01, a decrease of $2.40, highlighting market concerns regarding the company's future prospects, which may affect investor confidence and its ability to raise funds.
- Legal Implications: Pomerantz LLP is a prominent law firm specializing in class action litigation related to securities fraud and corporate misconduct, and if the lawsuit succeeds, Regenxbio could face substantial damages, further exacerbating its financial pressures.
See More
REGENXBIO Faces Securities Litigation Investigation
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities fraud claims against REGENXBIO related to securities transactions from February 9, 2022, to January 27, 2026, with a deadline for investors to apply as lead plaintiffs by April 14, 2026, highlighting the urgency and significance of the case.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that its gene therapies RGX-111 and RGX-121 faced clinical holds from the FDA due to a tumor case in a participant, leading to a 17.9% drop in stock price on the same day, significantly impacting investor confidence.
- Investor Loss Warning: The company's failure to disclose material adverse facts regarding the efficacy and safety of RGX-111 may result in substantial financial losses for investors, prompting Faruq & Faruq to encourage affected investors to contact them directly to discuss legal options, demonstrating a commitment to investor rights.
- Class Action Opportunity: Any eligible investor can apply to serve as lead plaintiff through counsel or choose to remain absent, indicating the collective nature of the lawsuit and its potential impact on investors, emphasizing the complexity of legal proceedings and the rights of investors.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, achieving the largest securities class action settlement against a Chinese company in 2017, showcasing its strong track record and expertise in this field.
- Participation Instructions: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, emphasizing the importance of selecting qualified legal counsel, especially since the class has not yet been certified, leaving investors to choose their representation wisely.
See More
REGENXBIO Announces Positive Interim Data for RGX-202 in Duchenne Muscular Dystrophy Trial
- Clinical Trial Progress: REGENXBIO has announced positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, indicating significant improvements in functionality, safety, and biomarkers, positioning it as a potential best-in-class gene therapy for Duchenne muscular dystrophy.
- Expert Data Presentation: The trial's principal investigator, Dr. Carolina Tesi-Rocha, Clinical Professor of Neurology at Stanford University School of Medicine, presented these findings at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, enhancing the therapy's academic recognition and industry visibility.
- Cardiac MRI Assessments: The new data includes cardiac MRI evaluations, suggesting RGX-202's potential in improving cardiac function, which is crucial for the overall health of Duchenne muscular dystrophy patients and may influence future treatment protocols.
- Optimistic Market Outlook: With positive clinical feedback, REGENXBIO is poised to carve out a niche in the competitive gene therapy market, attracting investor interest and potentially driving up the company's stock price.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and potentially receive compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, significantly reducing the financial burden on investors.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting the critical importance of transparency in corporate communications.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, which underscores the importance of selecting qualified legal counsel.
See More
REGENXBIO Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against REGENXBIO for violations of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that REGENXBIO made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth was revealed, indicating material misleading throughout the class period.
- Market Reaction: Following the revelation of REGENXBIO's true situation, investors experienced substantial losses, suggesting that the company's failure in information disclosure could have long-term negative impacts on its stock price.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to join the lawsuit for potential recovery, highlighting the legal avenue available for investors to seek compensation for their losses.
See More
Regenxbio Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regenxbio, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by April 14, 2026, indicating significant legal risks that could impact the company's reputation and stock price.
- FDA Clinical Hold: On January 28, 2026, Regenxbio announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case found in trials, leading to a 17.9% drop in stock price on the same day, reflecting the direct impact of regulatory risks on the company's operations.
- Significant Stock Decline: Following the FDA announcement, Regenxbio's stock price fell from $13.41 to $11.01, a decrease of $2.40, highlighting market concerns regarding the company's future prospects, which may affect investor confidence and its ability to raise funds.
- Legal Implications: Pomerantz LLP is a prominent law firm specializing in class action litigation related to securities fraud and corporate misconduct, and if the lawsuit succeeds, Regenxbio could face substantial damages, further exacerbating its financial pressures.
See More
REGENXBIO Faces Securities Litigation Investigation
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities fraud claims against REGENXBIO related to securities transactions from February 9, 2022, to January 27, 2026, with a deadline for investors to apply as lead plaintiffs by April 14, 2026, highlighting the urgency and significance of the case.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that its gene therapies RGX-111 and RGX-121 faced clinical holds from the FDA due to a tumor case in a participant, leading to a 17.9% drop in stock price on the same day, significantly impacting investor confidence.
- Investor Loss Warning: The company's failure to disclose material adverse facts regarding the efficacy and safety of RGX-111 may result in substantial financial losses for investors, prompting Faruq & Faruq to encourage affected investors to contact them directly to discuss legal options, demonstrating a commitment to investor rights.
- Class Action Opportunity: Any eligible investor can apply to serve as lead plaintiff through counsel or choose to remain absent, indicating the collective nature of the lawsuit and its potential impact on investors, emphasizing the complexity of legal proceedings and the rights of investors.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants provided misleading information regarding the development of RGX-111 gene therapy, claiming positive biomarker and safety data while concealing material adverse facts about the therapy's efficacy and safety, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, achieving the largest securities class action settlement against a Chinese company in 2017, showcasing its strong track record and expertise in this field.
- Participation Instructions: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, emphasizing the importance of selecting qualified legal counsel, especially since the class has not yet been certified, leaving investors to choose their representation wisely.
See More
